Clovis Oncology, Inc.: M&A transaction — Clovis Oncology completes sale of Rubraca assets to pharma& Schweiz under Chapter 11

Clovis Oncology, Inc.

On May 1, 2023, Clovis closed the Rubraca asset sale to pharma& Schweiz GmbH, following court approval on April 12.
Common stockholders are not expected to receive any payment due to senior creditor claims.
Sale was part of Chapter 11 bankruptcy proceedings initiated in December 2022.

item 2.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Clovis Oncology, Inc. completed a disposition involving pharma& Schweiz GmbH (closed 2023-05-01).

Action: disposition
Counterparty: pharma& Schweiz GmbH
Closing: 2023-05-01

Exact text from the filing

On May 1, 2023, the Company and Pharma& consummated the Rubraca Sale Transaction.

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001193125-23-130464

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.